Biomarin Pharmaceutical Inc (BMRN)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | 484,214 | 337,026 | 253,658 | 198,772 | 172,714 | 133,995 | 101,053 | 74,639 | 149,562 | 108,182 | 57,380 | 29,900 | -82,341 | -67,976 | -70,698 | -123,315 | -43,440 | -1,087 | 58,864 | 58,455 |
| Total assets | US$ in thousands | 6,988,940 | 6,851,200 | 7,067,120 | 6,872,670 | 6,841,600 | 6,758,160 | 6,563,170 | 6,433,700 | 6,375,070 | 6,264,040 | 6,145,840 | 6,062,710 | 6,004,770 | 5,977,480 | 5,898,500 | 5,805,050 | 5,848,020 | 6,158,090 | 5,302,110 | 4,722,840 |
| Operating ROA | 6.93% | 4.92% | 3.59% | 2.89% | 2.52% | 1.98% | 1.54% | 1.16% | 2.35% | 1.73% | 0.93% | 0.49% | -1.37% | -1.14% | -1.20% | -2.12% | -0.74% | -0.02% | 1.11% | 1.24% |
December 31, 2024 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $484,214K ÷ $6,988,940K
= 6.93%
The operating return on assets (Operating ROA) of Biomarin Pharmaceutical Inc has shown fluctuations over the given time period. The trend indicates a gradual improvement in the company's operating efficiency and profitability.
From March 31, 2020, to September 30, 2021, the Operating ROA was consistently negative, suggesting that the company's operating income was insufficient to cover its total assets. This could be a concerning sign of inefficiency or operational challenges during that period.
However, starting from December 31, 2021, there was a positive turnaround in the Operating ROA, indicating that the company's operating income started generating a more favorable return on its assets. This positive trend continued, with the Operating ROA increasing steadily and significantly from December 31, 2021, to December 31, 2024, reaching a peak of 6.93%.
The increasing trend in Operating ROA implies that Biomarin Pharmaceutical Inc has been able to effectively utilize its assets to generate operating income, reflecting improved operational efficiency and overall financial performance. This positive trend bodes well for the company's profitability and economic value creation for its shareholders.
Peer comparison
Dec 31, 2024